Types of Cardiovascular Disease: Which Ones Are Being Studied With Stem Cell Therapy?

"Cardiovascular disease" is not one condition but a family of them, and stem cell and cell therapy research has not treated them equally. This article walks through the major subtypes — heart attack and coronary artery disease, heart failure (both reduced and preserved ejection fraction), refractory angina, peripheral artery disease, and congenital heart disease — and summarizes where the clinical evidence for cell-based treatment actually stands for each.

Why This Category Splits So Sharply by Subtype

Cardiovascular disease remains the leading cause of death worldwide, according to the World Health Organization, which attributes roughly a third of all global deaths to conditions in this category. That scale, combined with the fact that damaged heart muscle and narrowed blood vessels don't regenerate well on their own, is why cardiologists began testing stem and progenitor cells in heart patients earlier than almost any other field, with some human cardiac cell trials dating back more than 20 years. The results since have been a mix of hard lessons and real, unproven promise — and which one applies depends heavily on the subtype.

Heart Attack and Coronary Artery Disease: The Original Disappointment

Acute myocardial infarction (heart attack) is where cardiac cell therapy began, built on the hope that injecting a patient's own bone marrow cells into damaged heart muscle shortly after a heart attack could regrow tissue and improve survival. The largest test of that idea, the BAMI trial, enrolled 375 patients with acute MI and successful reperfusion and found no significant difference in two-year all-cause mortality between the bone marrow cell group (3.3%) and standard care (3.8%). Independent meta-analyses of earlier bone marrow mononuclear cell trials in acute MI reached similar conclusions: no consistent mortality or ejection fraction benefit. This remains cardiology's clearest example of a once-promising stem cell approach that rigorous, adequately powered trials failed to confirm.

Heart Failure: A Split Story by Type

Heart failure isn't one disease, and the distinction matters for cell therapy. In heart failure with reduced ejection fraction (HFrEF), where the heart's pumping chambers weaken, research has produced trials large enough to learn from. The Phase 3 CardiAMP-HF trial, delivering a patient's own bone marrow cells directly into the heart, missed its primary efficacy endpoint (a composite of death, major cardiac events, and six-minute walk distance at 12 months), but reported favorable safety and a trend toward reduced mortality and major adverse events at two years — encouraging, but not yet sufficient on its own. A separate randomized trial of lab-grown heart muscle cells in advanced heart failure likewise reported encouraging safety and functional signals, underscoring active research even though no approach here is FDA-approved.

Heart failure with preserved ejection fraction (HFpEF) — where the heart muscle stiffens rather than weakens — is a much earlier story. Scientists have proposed mesenchymal stem/stromal cells as a way to target the chronic inflammation increasingly believed to drive HFpEF, an active area of laboratory and mechanistic study. But human trial data specific to cell therapy in HFpEF remains limited, and no therapy has yet demonstrated clinical benefit in this population.

Refractory Angina and Chronic Myocardial Ischemia: A Genuinely Encouraging Signal

For patients with refractory angina — chest pain that persists despite maximal medical therapy and isn't eligible for further bypass or stenting — early results are some of the more encouraging in this category. An open-label roll-in cohort of the CardiAMP chronic myocardial ischemia trial reported improved exercise tolerance and reduced angina frequency at its six-month primary follow-up, with investigators describing the improvements as durable through longer follow-up — a real signal worth taking seriously. The caveat matters just as much: this is open-label, uncontrolled data, not yet the blinded, randomized confirmation needed before it becomes a proven option.

Peripheral Artery Disease and Critical Limb Ischemia

In peripheral artery disease, particularly its most severe form, critical limb ischemia (where blood flow loss threatens the limb), cell therapy has reached further than in almost any other cardiovascular subtype: India's regulator granted limited, conditional marketing approval to Stempeucel, an allogeneic (donor-derived) mesenchymal stem cell product, for critical limb ischemia due to Buerger's disease and atherosclerosis — reportedly the first such approval anywhere. It is not FDA-approved, and further controlled trials are underway globally to confirm benefit more broadly, but it is a genuine regulatory first for this subtype.

Congenital and Pediatric Heart Disease

Research also extends to structurally abnormal hearts present from birth. A recent pediatric trial testing stem cell therapy in children with a serious congenital heart defect missed its main efficacy goal, yet researchers noted a survival signal worth investigating further — again, real but unconfirmed.

Quick-Reference: Cardiovascular Subtypes and Where Research Stands

• Heart attack / coronary artery disease: Large trials have not shown a mortality benefit.
• HFrEF: Most-studied subtype; Phase 3 safety and trend data, not yet proven efficacy.
• HFpEF: Early mechanistic, lab-stage research only.
• Refractory angina / chronic ischemia: Encouraging open-label signals; controlled data still pending.
• Critical limb ischemia (PAD): Furthest along regulatorily, with a limited approval in India; not FDA-approved.
• Congenital/pediatric heart disease: Mixed results with a possible survival signal.

Bottom Line

Stem cell and cell therapy research in cardiovascular disease tells a subtype-specific story, not one unified verdict. Heart attack repair has been tested rigorously and hasn't panned out; HFpEF research is too early to judge; but refractory angina and critical limb ischemia show real, incomplete signals of benefit, and HFrEF keeps generating data serious enough to justify continued investment. No cardiovascular cell therapy is FDA-approved today, and anyone considering an option should ask specifically which subtype the evidence being shown actually applies to.